| 翻訳と辞書 |
| Autologous patient specific tumor antigen response ： ウィキペディア英語版 |
Autologous patient-specific tumor antigen response
Autologous patient-specific tumor antigen response (apSTAR) technology is a new cancer treatment procedure being developed by IMULAN BioTherapeutics, LLC and (Veterinary Cancer Therapeutics, LLC ) for comparative oncology.
Also known as laser-assisted immunotherapy, apSTAR is an experimental cancer treatment for solid tumors that uses an autologous vaccine-like approach to stimulate immune responses. Specifically, laser-assisted immunotherapy combines laser-induced ''in situ'' tumor devitalization with an immunoadjuvant for local immunostimulation.
==Principles of apSTAR==
The two principles underlying apSTAR are: local destruction of tumor by means of a laser combined with a photo-absorbing dye and stimulated immune response due to the application of an immunoadjuvant, but also due to increases in antigen accessibility caused by the destruction of the tumor. Both elements of this protocol are crucial. Since this method independently triggers the immune response in each individual, it does not depend upon cross reactivity in the expression of tumor-specific antigen between hosts (as is required in conventional antibody immunotherapy and vaccination.)
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Autologous patient-specific tumor antigen response」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|